{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:18:06Z","timestamp":1795025886744,"version":"4.10.2"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>Exposure to heavy metals is common. This exposure is related to environmental contamination of air, water and soil, occupational exposure, accumulation in food, tobacco, and other factors. Cadmium and lead are notable for their widespread contamination, long-lasting effects in the body, and renal as well as cardiovascular toxicity. Acute toxicity due to high-level exposure, as well as chronic low-level exposure are now well-established pathogenic entities. Both chronic renal failure and ischemic heart disease patients have been treated separately in recent studies with ethylenediaminetetraacetic acid (EDTA) chelation therapy. In patients with chronic kidney disease (serum creatinine: 1.5\u20134.0\u2009mg\/dL) and increased body lead burden, weekly low-dose chelation with calcium EDTA slowed the rate of decline in renal function in patients with diabetes and in non-diabetic patients. In patients with a history of myocardial infarction, the Trial to Assess Chelation Therapy study showed that EDTA chelation decreased the likelihood of cardiovascular events, particularly in patients with diabetes. However, heavy metal levels were not measured in this study. It is clear that more research is needed in this area. There is also a need to more frequently consider and test for the possibility of cadmium and lead toxicity in patients with increased risk, such as those with hypertension, diabetes mellitus, and chronic renal disease.<\/jats:p>","DOI":"10.1097\/crd.0000000000000304","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T10:18:09Z","timestamp":1581329889000},"page":"312-318","source":"Crossref","is-referenced-by-count":50,"title":["Heavy Metal Toxicity in Chronic Renal Failure and Cardiovascular Disease"],"prefix":"10.1097","volume":"28","author":[{"given":"Daniel","family":"Glicklich","sequence":"first","affiliation":[{"name":"Department of Medicine, Renal Transplant Office, New York Medical College, Westchester Medical Center, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook Teaching Hospital, Stony Brook, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.108.827121","article-title":"A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the Department of Veterans Affairs Normative Aging Study.","volume":"120","author":"Weisskopf","year":"2009","journal-title":"Circulation"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2015.152","article-title":"Environmental factors in cardiovascular disease.","volume":"12","author":"Cosselman","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ahj.2014.07.007","article-title":"Metal pollutants and cardiovascular disease: mechanisms and consequences of exposure.","volume":"168","author":"Solenkova","year":"2014","journal-title":"Am Heart J"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"k3310","DOI":"10.1136\/bmj.k3310","article-title":"Environmental toxic metal contaminants and risk of cardiovascular disease: systematic review and meta-analysis.","volume":"362","author":"Chowdhury","year":"2018","journal-title":"BMJ"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"k3435","DOI":"10.1136\/bmj.k3435","article-title":"Environmental metals and cardiovascular disease.","volume":"363","author":"Tellez-Plaza","year":"2018","journal-title":"Brit Med J"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"870125","DOI":"10.1155\/2011\/870125","article-title":"Heavy metal poisoning and cardiovascular disease.","volume":"2011","author":"Alissa","year":"2011","journal-title":"J Toxicol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.kint.2017.03.013","article-title":"The decline in kidney function with chromium exposure is exacerbated with co-exposure to lead and cadmium.","volume":"92","author":"Tsai","year":"2017","journal-title":"Kidney Int"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-130-1-199901050-00003","article-title":"Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial.","volume":"130","author":"Lin","year":"1999","journal-title":"Ann Intern Med"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJMoa021672","article-title":"Environmental lead exposure and progression of chronic renal diseases in patients without diabetes.","volume":"348","author":"Lin","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/sj.ki.5001505","article-title":"Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes.","volume":"69","author":"Lin","year":"2006","journal-title":"Kidney Int"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"707.e1","DOI":"10.1016\/j.amjmed.2006.01.005","article-title":"Low-level environmental exposure to lead and progressive chronic kidney diseases.","volume":"119","author":"Lin","year":"2006","journal-title":"Am J Med"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1093\/ndt\/gfm342","article-title":"Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases.","volume":"22","author":"Lin-Tan","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1053\/j.ajkd.2012.04.028","article-title":"Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens.","volume":"60","author":"Chen","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jama.2013.2107","article-title":"Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.","volume":"309","author":"Lamas","year":"2013","journal-title":"JAMA"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1681\/ASN.V133745","article-title":"Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States.","volume":"13","author":"Muntner","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/CRD.0000000000000012","article-title":"Cardiovascular risk assessment before and after kidney transplantation.","volume":"22","author":"Glicklich","year":"2014","journal-title":"Cardiol Rev"},{"issue":"suppl 1","key":"R22-20230903","first-page":"S1","article-title":"USRDS 2009 annual data report: atlas of end-stage renal disease in the United States.","volume":"55","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamacardio.2019.0375","article-title":"Risk of cardiovascular disease and mortality in young adults with end-stage renal disease: an analysis of the US renal data system.","volume":"4","author":"Modi","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1681\/ASN.2009010025","article-title":"Change in estimated GFR associates with coronary heart disease and mortality.","volume":"20","author":"Matsushita","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJM199205073261916","article-title":"Lead levels in preindustrial humans.","volume":"326","author":"Flegal","year":"1992","journal-title":"N Engl J Med"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1289\/ehp.9783","article-title":"The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues.","volume":"115","author":"Hu","year":"2007","journal-title":"Environ Health Perspect"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/aje\/kwp248","article-title":"Blood cadmium and lead and chronic kidney disease in US adults: a joint analysis.","volume":"170","author":"Navas-Acien","year":"2009","journal-title":"Am J Epidemiol"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJMra1813869","article-title":"Chronic kidney disease of Uunknown cause in agricultural communities.","volume":"380","author":"Johnson","year":"2019","journal-title":"N Engl J Med"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMe020164","article-title":"Increased body lead burden\u2013cause or consequence of chronic renal insufficiency?.","volume":"348","author":"Marsden","year":"2003","journal-title":"N Engl J Med"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"59","DOI":"10.15585\/mmwr.mm6355a5","article-title":"Elevated blood lead levels among employed adults-United States, 1994-2013.","volume":"63","author":"Alarcon","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1097\/JOM.0b013e3181bf6c8d","article-title":"Bone lead level prediction models and their application to examine the relationship of lead exposure and hypertension in the third national health and nutrition examination survey.","volume":"51","author":"Park","year":"2009","journal-title":"J Occup Environ Med"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000183696","article-title":"Urinary lead excretion in uremic patients.","volume":"42","author":"Behringer","year":"1986","journal-title":"Nephron"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2174\/0929867053764635","article-title":"Metals, toxicity and oxidative stress.","volume":"12","author":"Valko","year":"2005","journal-title":"Curr Med Chem"},{"issue":"4 pt 1","key":"R38-20230903","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.HYP.34.4.558","article-title":"Nitric oxide synthase expression in the course of lead-induced hypertension.","volume":"34","author":"Vaziri","year":"1999","journal-title":"Hypertension"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0162-3109(99)00115-0","article-title":"Kininergic system and arterial hypertension following chronic exposure to inorganic lead.","volume":"44","author":"Carmignani","year":"1999","journal-title":"Immunopharmacology"},{"key":"R40-20230903","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/ATVBAHA.109.190082","article-title":"Cadmium is a novel and independent risk factor for early atherosclerosis mechanisms and in vivo relevance.","volume":"29","author":"Messner","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R41-20230903","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cbic.200800511","article-title":"The metallothionein\/thionein system: an oxidoreductive metabolic zinc link.","volume":"10","author":"Bell","year":"2009","journal-title":"Chembiochem"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11883-013-0356-2","article-title":"Cadmium exposure and clinical cardiovascular disease: a systematic review.","volume":"15","author":"Tellez-Plaza","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1289\/ehp.6116","article-title":"Associations of renal function with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers.","volume":"111","author":"Weaver","year":"2003","journal-title":"Environ Health Perspect"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"e0161472","DOI":"10.1371\/journal.pone.0161472","article-title":"Lead-related genetic loci, cumulative lead exposure and incident coronary heart disease: the Normative Aging Study.","volume":"11","author":"Ding","year":"2016","journal-title":"PLoS One"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.ki.5001809","article-title":"Lead-related nephrotoxicity: a review of the epidemiologic evidence.","volume":"70","author":"Ekong","year":"2006","journal-title":"Kidney Int"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/ajkd.2002.33936","article-title":"Experimental lead nephropathy: treatment with calcium disodium ethylenediaminetetraacetate.","volume":"40","author":"S\u00e1nchez-Fructuoso","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R47-20230903","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJM199207163270303","article-title":"Impairment of renal function with increasing blood lead concentrations in the general population. The Cadmibel Study Group.","volume":"327","author":"Staessen","year":"1992","journal-title":"N Engl J Med"},{"key":"R48-20230903","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/oxfordjournals.aje.a117330","article-title":"Low-level lead exposure and renal function in the Normative Aging Study.","volume":"140","author":"Payton","year":"1994","journal-title":"Am J Epidemiol"},{"key":"R49-20230903","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3346\/jkms.2015.30.3.272","article-title":"Environmental heavy metal exposure and chronic kidney disease in the general population.","volume":"30","author":"Kim","year":"2015","journal-title":"J Korean Med Sci"},{"key":"R50-20230903","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM198307073090104","article-title":"Contribution of lead to hypertension with renal impairment.","volume":"309","author":"Batuman","year":"1983","journal-title":"N Engl J Med"},{"key":"R51-20230903","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/ndt\/11.9.1775","article-title":"Occult lead intoxication as a cause of hypertension and renal failure.","volume":"11","author":"S\u00e1nchez-Fructuoso","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"R52-20230903","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1001\/archinte.162.21.2443","article-title":"Blood lead levels and mortality.","volume":"162","author":"Lustberg","year":"2002","journal-title":"Arch Intern Med"},{"key":"R53-20230903","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1161\/01.CIR.0000130848.18636.B2","article-title":"Lead, cadmium, smoking, and increased risk of peripheral arterial disease.","volume":"109","author":"Navas-Acien","year":"2004","journal-title":"Circulation"},{"key":"R54-20230903","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/CIRCULATIONAHA.106.628321","article-title":"Blood lead below 0.48 micromol\/L (10 microg\/dL) and mortality among US adults.","volume":"114","author":"Menke","year":"2006","journal-title":"Circulation"},{"key":"R55-20230903","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2468-2667(18)30025-2","article-title":"Low-level lead exposure and mortality in US adults: a population-based cohort study.","volume":"3","author":"Lanphear","year":"2018","journal-title":"Lancet Public Health"},{"key":"R56-20230903","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.jhh.1001300","article-title":"An epidemiologic reappraisal of the association between blood pressure and blood lead: a meta-analysis.","volume":"16","author":"Nawrot","year":"2002","journal-title":"J Human Hypertens"},{"key":"R57-20230903","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1289\/ehp.9785","article-title":"Lead exposure and cardiovascular disease\u2013a systematic review.","volume":"115","author":"Navas-Acien","year":"2007","journal-title":"Environ Health Perspect"},{"key":"R58-20230903","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1289\/ehp.10764","article-title":"Cadmium exposure and hypertension in the 1999-2004 National Health and Nutrition Examination Survey (NHANES).","volume":"116","author":"Tellez-Plaza","year":"2008","journal-title":"Environ Health Perspect"},{"key":"R59-20230903","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.lfs.2006.05.007","article-title":"The vascular endothelium as a target of cadmium toxicity.","volume":"79","author":"Prozialeck","year":"2006","journal-title":"Life Sci"},{"key":"R60-20230903","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.taap.2009.03.007","article-title":"Cadmium, diabetes and chronic kidney disease.","volume":"238","author":"Edwards","year":"2009","journal-title":"Toxicol Appl Pharmacol"},{"key":"R61-20230903","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2458-10-304","article-title":"Low level exposure to cadmium increases the risk of chronic kidney disease: analysis of the NHANES 1999-2006.","volume":"10","author":"Ferraro","year":"2010","journal-title":"BMC Pub Health"},{"key":"R62-20230903","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1053\/ajkd.2001.28589","article-title":"Cadmium exposure and end-stage renal disease.","volume":"38","author":"Hellstr\u00f6m","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R63-20230903","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1289\/ehp.11236","article-title":"Cadmium levels in urine and mortality among U.S. adults.","volume":"117","author":"Menke","year":"2009","journal-title":"Environ Health Perspect"},{"key":"R64-20230903","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1289\/ehp.1104352","article-title":"Cadmium exposure and all-cause and cardiovascular mortality in the U.S. general population.","volume":"120","author":"Tellez-Plaza","year":"2012","journal-title":"Environ Health Perspect"},{"key":"R65-20230903","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/EDE.0b013e31828b0631","article-title":"Cadmium exposure and incident cardiovascular disease.","volume":"24","author":"Tellez-Plaza","year":"2013","journal-title":"Epidemiology"},{"key":"R66-20230903","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1289\/ehp.7329","article-title":"Metals in urine and peripheral arterial disease.","volume":"113","author":"Navas-Acien","year":"2005","journal-title":"Environ Health Perspect"},{"key":"R67-20230903","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3109\/15563650903321064","article-title":"A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning.","volume":"47","author":"Bradberry","year":"2009","journal-title":"Clin Toxicol (Phila)"},{"key":"R68-20230903","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nep.12162","article-title":"Is lead chelation therapy effective for chronic kidney disease? A meta-analysis.","volume":"19","author":"Yang","year":"2014","journal-title":"Nephrology"},{"key":"R69-20230903","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/B:BIOM.0000029440.23884.d6","article-title":"Lack of reversal effect of EDTA treatment on cadmium induced renal dysfunction: a fourteen-year follow-up.","volume":"17","author":"Wu","year":"2004","journal-title":"Biometals"},{"key":"R70-20230903","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1385\/BTER:83:3:207","article-title":"EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc.","volume":"83","author":"Waters","year":"2001","journal-title":"Biol Trace Elem Res"},{"key":"R71-20230903","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.envres.2017.06.039","article-title":"Enhanced vasculotoxic metal excretion in post-myocardial infarction patients following a single edetate disodium-based infusion.","volume":"158","author":"Arenas","year":"2017","journal-title":"Environ Res"},{"key":"R72-20230903","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/j.1552-4604.1998.tb04397.x","article-title":"Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane.","volume":"38","author":"Elihu","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"R73-20230903","first-page":"204","article-title":"Deaths associated with hypocalcemia from chelation therapy-Texas, Pennsylvania and Oregon, 2003-2005.","volume":"55","year":"2006","journal-title":"MMWR"},{"key":"R74-20230903","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11886-015-0656-y","article-title":"EDTA chelation therapy to reduce cardiovascular events in persons with diabetes.","volume":"17","author":"Ouyang","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"R75-20230903","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2261-5-32","article-title":"EDTA chelation therapy for cardiovascular disease: a systematic review.","volume":"5","author":"Seely","year":"2005","journal-title":"BMC Cardiovasc Disord"},{"key":"R76-20230903","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0002-9343(01)01056-7","article-title":"Chelation therapy for coronary artery disease: panacea or quackery?.","volume":"111","author":"Frishman","year":"2001","journal-title":"Am J Med"},{"key":"R77-20230903","first-page":"CD002785","article-title":"Chelation therapy for atherosclerotic cardiovascular disease.","author":"Dans","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"R78-20230903","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jacl.2015.09.005","article-title":"Chelation therapy in the treatment of cardiovascular diseases.","volume":"10","author":"Ibad","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R79-20230903","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0002-9610(91)90172-A","article-title":"Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis.","volume":"162","author":"Sloth-Nielsen","year":"1991","journal-title":"Am J Surg"},{"key":"R80-20230903","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2796.1992.tb00533.x","article-title":"EDTA treatment of intermittent claudication\u2013a double-blind, placebo-controlled study.","volume":"231","author":"Guldager","year":"1992","journal-title":"J Intern Med"},{"key":"R81-20230903","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/01.CIR.90.3.1194","article-title":"Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial.","volume":"90","author":"van Rij","year":"1994","journal-title":"Circulation"},{"key":"R82-20230903","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jama.287.4.481","article-title":"Chelation therapy for ischemic heart disease: a randomized controlled trial.","volume":"287","author":"Knudtson","year":"2002","journal-title":"JAMA"},{"key":"R83-20230903","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0735-1097(02)02770-5","article-title":"Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy.","volume":"41","author":"Anderson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R84-20230903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ahj.2011.10.002","article-title":"Design of the Trial to Assess Chelation Therapy (TACT).","volume":"163","author":"Lamas","year":"2012","journal-title":"Am Heart J"},{"key":"R85-20230903","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/CIRCOUTCOMES.113.000714","article-title":"Are concerns about reliability in the trial to assess chelation therapy fair grounds for a hasty dismissal?: an alternative perspective.","volume":"7","author":"Kaul","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R86-20230903","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2014.02.012","article-title":"EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: the factorial group results of the Trial to Assess Chelation Therapy.","volume":"168","author":"Lamas","year":"2014","journal-title":"Am Heart J"},{"key":"R87-20230903","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ahj.2014.03.008","article-title":"Trial to Assess Chelation Therapy (TACT) and equipoise: when evidence conflicts with beliefs.","volume":"168","author":"Maron","year":"2014","journal-title":"Am Heart J"},{"key":"R88-20230903","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2016.02.066","article-title":"Heavy metals, cardiovascular disease, and the unexpected benefits of chelation therapy.","volume":"67","author":"Lamas","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R89-20230903","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jama.2013.2778","article-title":"Concerns about reliability in the Trial to Assess Chelation Therapy (TACT).","volume":"309","author":"Nissen","year":"2013","journal-title":"JAMA"},{"key":"R90-20230903","first-page":"115","article-title":"Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned.","volume":"10","author":"Atwood","year":"2008","journal-title":"Medscape J Med"},{"key":"R91-20230903","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10557-017-6759-5","article-title":"Chelation therapy as a cardiovascular therapeutic strategy: the rationale and the data in review.","volume":"31","author":"Mathew","year":"2017","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T05:12:47Z","timestamp":1693717967000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000304"}},"subtitle":["Possible Role for Chelation Therapy"],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000304","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,6]]}}}